The IJTLD is evolving. Alongside research on TB, we cover related respiratory diseases such as asthma, bronchiectasis, COVID-19, COPD, child lung health and the hazards of tobacco and air pollution.
A subscription provides unrestricted access to all our content including Editorials, Original Articles and Correspondence, alongside new article formats for Minireviews, Clinical Standards, Letters and Literature Highlights. Our impact factor is also growing – the 2022 Impact factor is 4.0.
Individuals and Institutes can subscribe to the IJTLD online, simply e-mail us at subscription@theunion.org
Funding agencies (including WHO and Gates Foundation) have recently mandated that authors must publish exclusively in fully-OA journals.
Our response to this change is to maintain the IJTLD for authors in LMICs who lack OA funding, while also launching a new title, IJTLD OPEN. This allows us to have a fully compliant OA journal that will enhance our coverage of TB and lung disease.
Both journals have the same Editorial Board with an identical peer review process and acceptance criteria. The only difference occurs after acceptance – authors with OA funding will be published in IJTLD OPEN.
The latest peer-reviewed articles on TB and HIV; respiratory diseases such as asthma and COPD; and the hazards of tobacco and air pollution. Recent coverage has expended to include COVID-19 and the interplay between TB-COVID-19 and other co-morbidities.
Individuals and institutes can subscribe to the IJTLD online – see our Subscription information or e-mail us at subscription@theunion.org for details.
We recently launched the IJTLD Clinical Standards for Lung Health, for optimal management of patients.
Thanks to the support of the Oskar-Helene-Heim Foundation and the Günther Labes Foundation, the first four Clinical Standards are Open Access and freely available to our global audience of clinicians and healthcare workers.
The series launched with Clinical standards for the assessment, management and rehabilitation of post-TB lung disease followed by Clinical standards for the diagnosis, treatment and prevention of TB infection, Clinical standards for the dosing and management of TB drugs and Clinical standards for drug-susceptible pulmonary TB.
Advertising or sponsoring content is an effective means of reaching clinicians, researchers, health workers, decision makers and students.
Sponsors can support the creation of a Collection or a Supplement on a relevant topic of interest, either in print or a digital collection of articles, for elevated visibility of your products and services.
Other opportunities include being involved in the creation of informative Posters, Infographics, or scientific Animations to clarify relevant biological processes.
IJTLD Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD and publishing them in full on our website, prior to their publication in the Journal. Read fast-track articles:
An update on the IJTLD: our latest impact factor and influence on policy-making
An Editorial in a forthcoming issue of the IJTLD describes improvements to our impact factor and influence on policy making.
Update on IJTLD OPEN: the future is open
An Editorial in a forthcoming issue of IJTLD OPEN provides highlights of progress made to date and the benefits of open access publishing.
Loss to follow-up among adults with drug-resistant TB in Papua New Guinea
An article in a forthcoming issue of PHA assesses the reasons for loss-to-follow-up in patients being treated for disease resistant TB.
Other versions of the journal
The IJTLD has been published in several languages, and publishes the Union World Conference abstract book each year.
Contact
For all IJTLD enquiries, please contact the IJTLD Editorial Office.